EU CHMP OKs New Treatments For MS, Esophagitis, CMV, Hemophilia – & First Biosimilar Avastin
Executive Summary
The EMA’s scientific committee, the CHMP, has given the green light to new treatments for multiple sclerosis, eosinophilic esophagitis, CMV, hemophilia A, and vaginal atrophy, as well as the EU’s first biosimilar version of Roche’s Avastin. The committee upheld two earlier negative opinions, and two products have been withdrawn from the assessment process.
You may also be interested in...
First Biosimilar Neulasta In Final Stages Of EMA Review Process
A biosimilar version of Amgen’s Neulasta has yet to be approved in the EU but one such product is in the later stages of review at the European Medicines Agency.
First Biosimilar Neulasta In Final Stages Of EMA Review Process
A biosimilar version of Amgen’s Neulasta has yet to be approved in the EU but one such product is in the later stages of review at the European Medicines Agency.
AstraZeneca’s Benralizumab Asthma Chase Gets Underway
Watch out GlaxoSmithKline and Teva: AstraZeneca's benralizumab has wind in its sails following a EU CHMP positive opinion for severe asthma. Approval in the US is also expected by year end.